09:56 AM EST - HLS Therapeutics Inc. : Announces its financial results for the three--month periods ended September 30, 2022. All amounts are in thousands of United States dollars unless otherwise stated. Revenue was $15.7 million compared to $15.1 million in Q3 2021, and up 7% to $16.1 million measured at constant currency.Net loss was ($4.4) million, or ($0.14) per common share, compared to net loss of ($2.0) million, or ($0.06) per common share, in Q3 2021. HLS Therapeutics Inc.
shares T.HLS are trading unchanged at $9.50.
